Exchange: NASDAQ·Updated 07:53 PM EDT

IRD News

News
all
press releases
Biotech Whiplash: Big Pharma Setbacks Just Created a New Wave of Rebound Plays
The biotech tape delivered a brutal reminder of one of the sector’s oldest rules: a great company can get crushed by bad news somewhere else in the pipeline. A Novartis (NYSE:NVS) setback rippled through the biotech space, yesterday, dragging down companies whose own announcements were positive.
24-7 Market News
More News
IRD Stock Hits Over 5-Year Highs – Opus Genetics Experimental Therapy Shows Early Promise In Retinal Diseases Trial
Researchers observed structural improvements in the retina in four of five patients being evaluated in a Phase 1/2 study
Stocktwits
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF) stockread more...
Benzinga
Five Market Stories Heating Up Right Now
The latest market developments are putting investors’ attention back on tangible catalysts: NeOnc Technologies Holdings (NASDAQ:NTHI) is pairing fresh institutional capital with encouraging NEO100 clinical data; Opus Genetics (NASDAQ:IRD) is advancing OPGx-BEST1 toward potential pivotal development after positive early data and FDA feedback; bioAffinity Technologies (NASDAQ:BIAF) removed its Nasdaq compliance overhang while continuing to commercialize CyPath Lung; Tenon Medical (NASDAQ:TNON) eliminated roughly $5.16 million of convertible-note obligations ahead of maturity; Sunation Energy (NASDAQ:SUNE) is positioned at the center of Suniva’s $835 million financing and planned expansion to 5.5 GW of U.S. solar-cell capacity; and The OLB Group (NASDAQ:OLB) is attempting to build a rebound momentum after recently hitting a new 52-week low and, yes, I know that’s a sixth company.
24-7 Market News
Gene Therapy at Lower Dose Shows Vision Improvements, Opus Genetics Says
Opus Genetics posts positive Phase 1/2 trial results for OPGx-BEST1 and aligns with the FDA on Phase 3 plans for 2027.read more...
Benzinga
Caleres Posts Upbeat Q2 Earnings, Joins Opus Genetics, Flotek Industries And Other Big Stocks Moving Higher On Wednesday
U.S. stocks fell, but Caleres surged 14% on strong results and higher guidance. Opus Genetics, Signet and Oddity also posted big gains.read more...
Benzinga
Five High-Voltage Stories in Focus
The market is once again rewarding investors who know where to look for catalysts, bioAffinity Technologies (NASDAQ:BIAF), NeOnc Technologies Holdings (NASDAQ:NTHI), Opus Genetics (NASDAQ:IRD), Eos Energy Enterprises (NASDAQ:EOSE) with Google (NASDAQ:GOOG), and Scorpio Gold (NASDAQ:SGLD) each have a distinctly different catalyst driving their narratives.
24-7 Market News
Opus Genetics, Inc. (IRD) Reports Q2 Loss, Lags Revenue Estimates
Opus Genetics, Inc. (IRD) delivered earnings and revenue surprises of +6.67% and -75.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Qiagen (QGEN) Beats Q2 Earnings and Revenue Estimates
Qiagen (QGEN) delivered earnings and revenue surprises of +3.33% and +1.35%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup
RBC Capital Bullish On Opus Genetics (IRD) Amid Limited Competition And De-Risked Setup...
Yahoo! Finance: News

Advertisement|Remove ads.